State Street Corp lifted its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 1.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 15,208,875 shares of the medical instruments supplier’s stock after purchasing an additional 208,811 shares during the quarter. State Street Corp owned about 0.06% of Becton, Dickinson and Company worth $2,722,389,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in BDX. BlackRock Inc. bought a new position in shares of Becton, Dickinson and Company in the second quarter worth about $3,721,533,000. Bank of America Corp DE bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $474,993,000. First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after purchasing an additional 1,887,224 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $247,372,000. Finally, Deutsche Bank AG acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $204,226,000. Institutional investors own 86.97% of the company’s stock.
Becton, Dickinson and Company Price Performance
Shares of BDX stock opened at $212.19 on Friday. Becton, Dickinson and Company has a 52-week low of $140.11 and a 52-week high of $220.36. The stock has a market cap of $58.47 billion, a PE ratio of 51.25, a PEG ratio of 3.56 and a beta of 0.22. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87. The firm’s 50 day moving average price is $194.40 and its two-hundred day moving average price is $170.85.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The company had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. During the same quarter in the prior year, the business posted $3.96 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. As a group, analysts forecast that Becton, Dickinson and Company will post 13.21 EPS for the current year.
Becton, Dickinson and Company declared that its Board of Directors has initiated a stock repurchase plan on Thursday, November 5th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 3.6% of its stock through open market purchases. Share repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.
Becton, Dickinson and Company Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be given a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Thursday, December 10th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio is presently 101.45%.
Insider Activity
In other news, CEO Thomas Polen, Jr. sold 2,993 shares of the company’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $210.00, for a total value of $628,530.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $23,134,230. This represents a 2.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,310 shares of company stock valued at $688,650 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.
Analyst Ratings Changes
Several research firms have issued reports on BDX. Weiss Ratings raised Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, November 4th. Wolfe Research started coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They issued an “outperform” rating for the company. Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a research note on Friday, November 6th. Bank of America boosted their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Monday, August 31st. Finally, Barclays upped their price target on Becton, Dickinson and Company from $165.00 to $195.00 and gave the company an “underweight” rating in a research note on Tuesday, November 10th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $197.47.
Check Out Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
See Also
- Five stocks we like better than Becton, Dickinson and Company
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
